Filing Flows › Embecta (EMBC) › Q3 FY26
Embecta (EMBC) Q3 FY26 earnings results (third quarter fiscal 2026)
10-Q filed Aug 7, 2026
Embecta (EMBC) reported revenue of $272M for the third quarter fiscal 2026 (Q3 FY26), -8% from a year earlier and +22% from the quarter before. Operating margin was 17.9%, net earnings $21.1M (7.8% of revenue).
Embecta, Q3 FY26: revenue $272M (-8% year over year), operating margin 17.9%, net earnings $21.1M, operating cash flow $41.8M. The chart follows the revenue to costs, profit and cash.
| Q3 FY26 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $272M | +22% | -8% |
| Gross profit | $153M | +20% | -22% |
| Operating profit | $48.7M | +39% | -48% |
| Net earnings | $21.1M | — | -54% |
| Operating cash flow | $41.8M | +34% | -49% |
| Free cash flow | $40.7M | — | -50% |
What changed
Revenue was $271.7M in Q3 FY26, down 8% year over year and up 22% from the previous quarter. Pen Needles was the largest line at 65% of revenue. Pen Needles lost $39.4M year over year (down 18%), 166% of the total change.
Gross margin was 56.4%, down 10.3 points from Q3 FY25. Operating profit was $48.7M, a 17.9% margin (down 13.9 points year over year). Operating expenses grew 1% against a revenue fall of 8%. The fastest-growing cost line was Other operating costs (+43%). Net earnings were $21.1M, down 54% year over year. The effective tax rate was 23.6%.
Operating cash flow was $41.8M (down 49% year over year), 198% of net earnings. Non-cash charges added back $10.6M of depreciation and amortization and $4.2M of share-based compensation. Working capital and other items added $5.9M. After capital expenditures ($1.1M), free cash flow as the company reports it was $40.7M.
Questions
What was Embecta's revenue in the third quarter fiscal 2026?
Embecta (EMBC) reported revenue of $272M for the third quarter fiscal 2026 (Q3 FY26), -8% from a year earlier and +22% from the quarter before.
Was Embecta profitable in the third quarter fiscal 2026?
Operating profit was $48.7M (17.9% of revenue) and net earnings $21.1M.
Source: Embecta 10-Q on SEC EDGAR.